Colorectal Cancer Screening & Diagnostic Market by Product Type, Age Group, End-use

Description

List of Tables

The Colorectal Cancer Screening & Diagnostic Market was valued at USD 15.29 billion in 2023, expected to reach USD 16.21 billion in 2024, and is projected to grow at a CAGR of 6.28%, to USD 23.43 billion by 2030.

The scope and definition of the colorectal cancer screening and diagnostic market encompass a range of methods and technologies aimed at early detection and diagnosis of colorectal cancer, which is essential for effective treatment and improved patient outcomes. This market includes tests such as colonoscopy, fecal occult blood testing (FOBT), flexible sigmoidoscopy, and newer non-invasive methods like DNA-based stool tests. The necessity for these screening and diagnostic methods stems from the high prevalence and mortality rates associated with colorectal cancer, particularly among individuals aged 50 and older or those with a family history of the disease. Key applications include early detection in asymptomatic individuals and monitoring disease progression in diagnosed patients, with end-users spanning hospitals, diagnostic laboratories, and outpatient care centers. The market is driven by factors such as increasing public awareness, advancements in biotechnology, and supportive government policies emphasizing preventive healthcare. Technological innovations such as AI-assisted imaging and at-home testing kits represent burgeoning opportunities, while collaboration with insurance companies can enhance accessibility. However, the market faces limitations like patient apprehension towards invasive procedures, high costs, and variability in test accuracy. Market growth is challenged by regulatory hurdles and limited healthcare infrastructure in developing regions. Areas of innovation include the development of cost-effective and minimally invasive tests, personalized screening protocols based on genetic insights, and integration of digital health tools for patient monitoring. The nature of this market is competitive, with ongoing R&D investments required for improvements. For business growth, companies should focus on strategic partnerships, enhancing test accuracy, and expanding into emerging markets where increased healthcare spending is anticipated. Overcoming challenges calls for addressing healthcare disparities, promoting increased awareness, and reducing associated costs for broader adoption.

KEY MARKET STATISTICS
Base Year [2023]	USD 15.29 billion
Estimated Year [2024]	USD 16.21 billion
Forecast Year [2030]	USD 23.43 billion
CAGR (%)	6.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Colorectal Cancer Screening & Diagnostic Market

The Colorectal Cancer Screening & Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing cases of colorectal cancer globally
- Rising government initiatives to promote early detection of colorectal cancer
Market Restraints
- High cost associated with colorectal cancer screening and diagnostic
Market Opportunities
- Growing funding and expenditure in the healthcare sector for cancer diagnosis and treatment
- Increase in the launch of new and advanced cancer diagnostic technologies
Market Challenges
- Concerns associated with post-colonoscopy complications

Porter's Five Forces: A Strategic Tool for Navigating the Colorectal Cancer Screening & Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Colorectal Cancer Screening & Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Colorectal Cancer Screening & Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Colorectal Cancer Screening & Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Colorectal Cancer Screening & Diagnostic Market

A detailed market share analysis in the Colorectal Cancer Screening & Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Colorectal Cancer Screening & Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Colorectal Cancer Screening & Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Colorectal Cancer Screening & Diagnostic Market

A strategic analysis of the Colorectal Cancer Screening & Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Colorectal Cancer Screening & Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Clinical Genomics Technologies Pty Ltd., Eiken Chemical Co., Ltd., Epigenomics AG, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Guardant Health, Hologic, Inc., Illumina, Inc., KARL STORZ SE & Co. KG, Medtronic PLC, Merck KGaA, Myriad Genetics, Inc., Novigenix SA, Olympus Corporation, Prenetics Global Limited, QIAGEN N.V., Quest Diagnostics Incorporated, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Colorectal Cancer Screening & Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product Type, market is studied across Instruments and Reagents & Kits.
Based on Age Group, market is studied across 19 to 65, Above 65, and Upto 18 Years.
Based on End-use, market is studied across Clinical Laboratories, Diagnostic Imaging Centers, and Hospitals & Clinics.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-5C6F41F5AF41

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing cases of colorectal cancer globally
  - 5.1.1.2. Rising government initiatives to promote early detection of colorectal cancer
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with colorectal cancer screening and diagnostic
- 5.1.3. Opportunities
  - 5.1.3.1. Growing funding and expenditure in the healthcare sector for cancer diagnosis and treatment
  - 5.1.3.2. Increase in the launch of new and advanced cancer diagnostic technologies
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with post-colonoscopy complications
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Colorectal Cancer Screening & Diagnostic Market, by Product Type

6.1. Introduction
6.2. Instruments
6.3. Reagents & Kits

7. Colorectal Cancer Screening & Diagnostic Market, by Age Group

7.1. Introduction
7.2. 19 to 65
7.3. Above 65
7.4. Upto 18 Years

8. Colorectal Cancer Screening & Diagnostic Market, by End-use

8.1. Introduction
8.2. Clinical Laboratories
8.3. Diagnostic Imaging Centers
8.4. Hospitals & Clinics

9. Americas Colorectal Cancer Screening & Diagnostic Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Colorectal Cancer Screening & Diagnostic Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Colorectal Cancer Screening & Diagnostic Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Abbott Laboratories
2. Agilent Technologies, Inc.
3. Bayer AG
4. Becton, Dickinson and Company
5. Bio-Rad Laboratories, Inc.
6. bioMerieux SA
7. Clinical Genomics Technologies Pty Ltd.
8. Eiken Chemical Co., Ltd.
9. Epigenomics AG
10. Exact Sciences Corp.
11. F. Hoffmann-La Roche Ltd.
12. Fujifilm Holdings Corporation
13. GE HealthCare Technologies, Inc.
14. Guardant Health
15. Hologic, Inc.
16. Illumina, Inc.
17. KARL STORZ SE & Co. KG
18. Medtronic PLC
19. Merck KGaA
20. Myriad Genetics, Inc.
21. Novigenix SA
22. Olympus Corporation
23. Prenetics Global Limited
24. QIAGEN N.V.
25. Quest Diagnostics Incorporated
26. Siemens AG
27. Sysmex Corporation
28. Thermo Fisher Scientific Inc.